Warts in cattle are caused by bovine papillomaviruses. While there are many different types of bovine papillomaviruses, the most common is called bovine papillomavirus 1 (BPV 1).
Historically, wart vaccines have consisted of large doses of chemically inactivated crude wart homogenates that raise concerns about safety and syringeability, as well as inconsistent availability.
Cambridge’s conditionally licensed bovine wart vaccine is produced using a baculovirus that is engineered to express the main surface protein of BPV 1.
The inactivated baculovirus culture expressing the BPV1surface protein is adjuvanted with our proprietary PS50 oil-in-water adjuvant to help stimulate a robust humoral immune response following subcutaneous administration.
The vaccine stimulates the bovine immune system to generate neutralizing antibodies. Trials in cattle have demonstrated neutralizing titers in calves following administration of our vaccine, which led to protection from the development of warts following challenge.
